D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
CTMX holding history
CytomX Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CTMX overviewAll 13F holders of CTMXFull Q2 2026 holdings
- Shares (Q2 2024)
- 0
- Sold out in Q2 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 12
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2024 | 0 | $0 | 0.0% | −10,811−100.0% | Sold out | Holders |
| Q1 2024 | 10,811 | $23.6K | <0.1% | −766−6.6% | Reduced | Holders |
| Q4 2023 | 11,577 | $17.9K | <0.1% | −61,917−84.2% | Reduced | Holders |
| Q3 2023 | 73,494 | $94.8K | <0.1% | −56,966−43.7% | Reduced | Holders |
| Q2 2023 | 130,460 | $224.4K | <0.1% | −170,381−56.6% | Reduced | Holders |
| Q1 2023 | 300,841 | $454.3K | <0.1% | −317,533−51.3% | Reduced | Holders |
| Q4 2022 | 618,374 | $989.4K | <0.1% | +128,744+26.3% | Added | Holders |
| Q3 2022 | 489,630 | $710.0K | <0.1% | +242,153+97.8% | Added | Holders |
| Q2 2022 | 247,477 | $453.0K | <0.1% | +77,526+45.6% | Added | Holders |
| Q1 2022 | 169,951 | $454.0K | <0.1% | +169,951 | New | Holders |
| Q4 2021 | 0 | $0 | 0.0% | −26,297−100.0% | Sold out | Holders |
| Q3 2021 | 26,297 | $134.0K | <0.1% | −163,147−86.1% | Reduced | Holders |
| Q2 2021 | 189,444 | $1.20M | <0.1% | −129,037−40.5% | Reduced | Holders |
| Q1 2021 | 318,481 | $2.46M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.